Heading
Heading
Dubai has just established The Dubai Longevity Authority (DLA).
The DLA is tasked with positioning Dubai as a leading global hub for healthy longevity, wellness and advanced healthcare, attracting investment into the sector and helping shape the future of healthcare.
The premise is straightforward: In the UK, Europe and elsewhere, businesses in the supplements, biotech, and longevity sectors have to navigate a regulatory maze full of bottlenecks, slow clinical trial approvals, and bureaucratic legacy frameworks. And the DLA seeks to address these systemic hurdles, offering businesses a streamlined, innovation-friendly launchpad.
1. Eliminating Regulatory Bottlenecks: DLA unifies oversight across R&D, manufacturing, and clinical delivery into a single transparent pipeline, bypassing the fragmented bureaucracy common in western markets.
2. Accelerating Clinical Trial Approvals: By modernising trial protocols and leveraging digitised approval workflows, companies can initiate trials and validate therapies in months rather than years.
3. Overcoming Legacy Constraints: DLA’s mandate specifically accommodates novel preventative, cellular, and anti-ageing interventions, providing clear legal pathways where legacy rules often leave cutting-edge science in regulatory limbo.
Dransfield Partners is a full-service law firm across the UK and UAE.
